about
Deep brain stimulation for Parkinson disease: an expert consensus and review of key issuesVoice and fluency changes as a function of speech task and deep brain stimulation.Spontaneous subarachnoid hemorrhage in an HIV patient.What's special about task in dystonia? A voxel-based morphometry and diffusion weighted imaging study.Deep brain stimulation for torsion dystonia in children.Treatment of levodopa-induced motor complications.Pallidal deep brain stimulation for primary dystonia in children.Early postoperative management of DBS in dystonia: programming, response to stimulation, adverse events, medication changes, evaluations, and troubleshooting.Long-Term management of DBS in dystonia: response to stimulation, adverse events, battery changes, and special considerations.Open-label surgical trials for Parkinson disease: time for reconsideration.Referring patients for deep brain stimulation: an improving practice.Deep brain stimulation in DYT1 dystonia: a 10-year experience.Sustained relief of generalized dystonia despite prolonged interruption of deep brain stimulation.Subthalamic deep brain stimulation with a constant-current device in Parkinson's disease: an open-label randomised controlled trial.Therapeutic high-frequency stimulation of the subthalamic nucleus in Parkinson's disease produces global increases in cerebral blood flow.Defining a therapeutic target for pallidal deep brain stimulation for dystonia.Sixty hertz pallidal deep brain stimulation for primary torsion dystonia.Factors predicting protracted improvement after pallidal DBS for primary dystonia: the role of age and disease duration.Longitudinal impedance variability in patients with chronically implanted DBS devices.Pallidal deep brain stimulation for DYT6 dystonia.Impaired sequence learning in carriers of the DYT1 dystonia mutation.Reply: Neural reorganization through deep brain stimulation: anything new on the horizon?Peripheral nerve function in HIV infection: clinical, electrophysiologic, and laboratory findings.Calculating total electrical energy delivered by deep brain stimulation systems.The rationale driving the evolution of deep brain stimulation to constant-current devices.Subthalamic deep brain stimulation and impulse control in Parkinson's disease.A multicenter, open-label, sequential study comparing preferences for carbidopa-levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson's disease.Outcome predictors of pallidal stimulation in patients with primary dystonia: the role of disease duration.Deep brain stimulation for primary generalized dystonia: long-term outcomes.Deep brain stimulation: can we do it better?A mixed D1 and D2 antagonist does not replay pattern electroretinogram alterations observed with a selective D2 antagonist in normal humans: relationship with Parkinson's disease pattern electroretinogram alterations.Lower stimulation frequency can enhance tolerability and efficacy of pallidal deep brain stimulation for dystonia.Turning tables: should GPi become the preferred DBS target for Parkinson disease?Intraoperative microelectrode recording equipment: what features are necessary?Improvement of both dystonia and tics with 60 Hz pallidal deep brain stimulation.Treating PD axial signs with DBS: is two better than one?Safety of MRI in patients with implanted deep brain stimulation devices.STN-DBS frequency effects on freezing of gait in advanced Parkinson disease.Fine-tuning gait in Parkinson disease.Lack of motor symptoms progression in Parkinson's disease patients with long-term bilateral subthalamic deep brain stimulation.
P50
Q22253049-844D7D93-9F63-40D4-931F-17B36AF64133Q30417282-E11F10BC-7050-4065-9352-72E063E32BF8Q33401945-4781A5B5-E2CE-4211-B7EF-458ACB241BB6Q34071172-689DF9B1-C34F-463E-9F6D-EE24CDF7A18EQ36841567-B054F48D-E63E-4BF9-BBC8-DD9AC82FBBC1Q37264482-5B164C5C-2677-43C8-8C5D-BECF2A477BACQ37821728-D1A28CC2-5714-48C8-9DD8-4C7C067FCBAEQ37892484-9273B260-C64F-4ACA-BEF5-77B400CB7EC9Q37892487-DCC3B8C3-9AEC-4CD6-95F9-101C2EE47D70Q37904918-46157EFF-7DBC-4C16-B12A-C56A976F87AEQ37913771-768E0372-C3D1-48A3-AD47-128F42AAA0E7Q38101414-FB8CA407-02F8-407A-825A-ED40A55103DFQ39232578-F8BA1D5C-212D-45F0-A95F-5C9AD8C9A52AQ39665047-044BA1F4-850C-46A3-B01E-78F3B8078C30Q42551351-36DEA77E-47A9-40A1-8AB0-B5FF25CD193EQ43422990-4D49F04E-DB27-4D18-B3F2-EF10E38D18B8Q43640625-6FC04BAD-6398-4B49-A333-B0F15778517EQ43923139-B07398B6-8012-4F76-8E6D-84C0FC490632Q44004017-81DE912C-4E1B-41A8-A11A-70F495690190Q44090647-1A63A984-C889-4737-823F-AA921557BF41Q44499886-FC4303EA-474B-4129-9DC5-D0C98F683583Q44555708-80969DF2-4C90-4CC9-93F1-1C01442FF2B7Q44754653-36AA273D-A28B-4F3D-8439-CC8A463B4973Q45297272-502F97A8-8027-493F-BD95-AB772D638699Q46044108-6BD8E0BF-337D-4310-BB22-CBE3A0370264Q46112637-80F3F7D7-4C54-4175-AA6C-C0A761B5C4F1Q46374110-5B02A28C-855D-435A-8EB8-E0842E50BE58Q47624482-C3418764-5A29-42D1-9283-50B723156460Q48012076-1A4E172C-8951-415B-ACF9-0D23FF8F093EQ48151966-105D1471-FBC0-4677-8BF4-B7478C88CCCCQ48199139-B5FEAC51-2812-45F3-9154-C8C3F6C72FA8Q48313162-86EC9E93-91A3-4F23-B996-94F61453FDCEQ48425391-67B9C4B5-B066-4E95-A626-9EF76888FC01Q48469354-E40E855B-A372-447E-A75E-08C3D0F6BBA9Q48573300-4830F2CC-957C-468A-862D-8F96A2B51609Q48622802-4C1FBFBF-F10C-441E-92A6-64F34C51BDF5Q48654743-D91ACED2-BA1B-4A5A-85B5-6BAE90BA5754Q48729599-9F7C988F-1599-481B-9E8B-80BFCD4B4125Q49113395-C6AAF9F1-8D57-4D24-AF80-BF5F1279133CQ50267093-4AFFF174-16F1-4AC4-AC77-B635DF62BA2B
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Michele Tagliati
@ast
Michele Tagliati
@en
Michele Tagliati
@es
Michele Tagliati
@nl
Michele Tagliati
@sl
type
label
Michele Tagliati
@ast
Michele Tagliati
@en
Michele Tagliati
@es
Michele Tagliati
@nl
Michele Tagliati
@sl
prefLabel
Michele Tagliati
@ast
Michele Tagliati
@en
Michele Tagliati
@es
Michele Tagliati
@nl
Michele Tagliati
@sl
P106
P1153
7004493578
P31
P496
0000-0002-6722-8208